Dengue and Dengue Hemorrhagic Fever | ||||
| Afro-Egyptian Journal of Infectious and Endemic Diseases | ||||
| Article 8, Volume 5, Issue 3, September 2015, Page 189-200 PDF (297.7 K) | ||||
| Document Type: Review article and meta analysis | ||||
| DOI: 10.21608/aeji.2015.17830 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Maysaa Abdallah Saeed  1; Tarek Hamed Attia2
| ||||
| 1Tropical Medicine Department, Faculty of Medicine, Zagazig University, Egypt.. | ||||
| 2Pediatric Department, Faculty of Medicine, Zagazig University, Egypt | ||||
| Abstract | ||||
| Dengue is endemic in at least 100 countries in Asia, the Pacific, the Americas, Africa, and the Caribbean. The World Health Organization (WHO) estimates that 50 to 100 million infections occur yearly, including 500,000 dengue hemorrhagic fever (DHF) cases and 22,000 deaths, mostly among children. Both epidemic and endemic transmission of dengue viruses are maintained through a human-mosquito-human cycle involving mosquitoes of the genus Aedes (Stegomyia). Typical clinical manifestations of dengue range from self-limited dengue fever (DF) to dengue hemorrhagic fever with shock syndrome. Most dengue virus infections in adults are symptomatic. In contrast, most infections among children under age 15 years are asymptomatic or minimally symptomatic. Classic dengue fever is an acute febrile illness accompanied by malaise, headache, retro orbital pain, and marked muscle and joint pains, which evoked the term "break-bone fever". DHF is the most serious manifestation of dengue virus infection and can be associated with circulatory failure and shock. Plasma leakage is the most specific and life-threatening feature of DHF. | ||||
| Keywords | ||||
| flaviviruses; Dengue virus; hemorrhagic fever | ||||
|
Statistics Article View: 232 PDF Download: 410 |
||||
